EUVIMED · CrossrefJournal
Journal of Medical Economics
ISSN 1369-6998 · Informa UK Limited
Latest articles
Clinical benefits and cost saving of achieving composite treatment targets for type 2 diabetes – A modeling study
A five-year cost-consequence analysis of extended-use etonogestrel implant versus other contraceptives
Cost comparison of osimertinib plus platinum-pemetrexed versus amivantamab plus lazertinib for the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer
Prolonged progression-free survival with zanubrutinib in relapsed/refractory CLL: an indirect treatment comparison versus other BTK inhibitors using multilevel network meta-regression
Economic burden of advanced non-small cell lung cancer (NSCLC): a systematic literature review
Modeling the cost-effectiveness of the next-generation COVID-19 mRNA-1283 vaccine in the United States
Cost-effectiveness of exagamglogene autotemcel gene-edited therapy in patients with sickle cell disease with recurrent vaso-occlusive crises in the United States
Clinical and economic benefits of combined genetic and genomic testing strategies to guide treatment decisions for patients with HR+/HER2– breast cancer in the US
Budget impact model of nadofaragene firadenovec for the treatment of high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin immunotherapy
Enhanced patient outcomes and improved budget impact from increased PFO diagnostic testing in cryptogenic stroke workup: a US hospital perspective
Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK
Return on investment of national specific health guidance in Japan: an observational study using “Wellness-Star⋆” health insurance claims database
Economic value of lost productivity attributable to premature cancer mortality and morbidity across Europe
Impact of offering blood-based testing alongside existing modalities for colorectal cancer screening among those who previously declined screening: an economic evaluation
Clinical and healthcare burden of myotonic dystrophy type 1 (DM1) in the United States: a claims-based study
Reply: clinical and methodological uncertainty in the economic evaluation of suzetrigine
Clinical and methodological uncertainty in the economic evaluation of suzetrigine
Publisher’s note
Healthcare burden of mixed aortic valve stenosis and insufficiency disease
Management of moderate-to-highly exuding leg ulcers with polyacrylate superabsorbent wound dressings versus foam dressings in spanish settings: an early-stage cost-effectiveness and budget-impact analysis
Employment and productivity losses from cervical spinal cord injury: a 7-year nationwide cohort study in Taiwan, 2012–2018
A systematic literature review of methodologies used in economic evaluations of combination vaccines
The full value of mRNA seasonal influenza and endemic-stage COVID-19 combination vaccines: a taxonomy
Cost per event avoided: adopt or avoid?
Cost-effectiveness of pembrolizumab plus chemotherapy vs cemiplimab plus chemotherapy for first-line metastatic non–small cell lung cancer: a US payer perspective using a matching-adjusted indirect comparison
Economic and clinical value of hydrolyzed collagen in the management of spine surgery wounds: a cost-effectiveness analysis
Analysis of healthcare resource utilization before and after initiation of maribavir for cytomegalovirus treatment
Real-world healthcare resource utilization and clinical outcomes among patients with relapsed/refractory multiple myeloma receiving ciltacabtagene autoleucel after four or more prior lines of therapy in inpatient versus outpatient settings
Bleeding rates, healthcare utilization, and costs among patients with hemophilia a without inhibitors treated with concomitant octocog alfa or extended half-life factor VIII while on emicizumab prophylaxis
Loss of productivity among commercially insured patients with pulmonary arterial hypertension in the United States
EUVIMED